Sirnaomics seals $105m Series D financing for RNAi therapeutics

This article was originally published here

This round of funding was co-led by existing investor Rotating Boulder Fund, new investor Walvax Biotechnology Co., Ltd. and Sunshine Riverhead Capital, with support from existing investors Sangel

The post Sirnaomics seals $105m Series D financing for RNAi therapeutics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply